Proposal to list Negative Pressure Wound Therapy equipment and consumables (NPWT Products) supplied by Protec Solutions Limited

Hospital devices

Consultation Closed

PHARMAC is seeking feedback on a proposal to list a range of NPWT Products supplied by Protec Solutions Limited (“Protec”) in Part III of Section H of the Pharmaceutical Schedule from 1 March 2018.

The consultation closes at 4 pm on Friday 2 February 2018 and feedback can be emailed to denise.mundy@pharmac.govt.nz.

What would the effect be?

From 1 March 2018, Protec’s NPWT Products would be listed under a proposed national agreement that all DHBs may purchase or rent under, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreement”).

DHBs would be able to continue to purchase or rent other suppliers’ brands of NPWT Products, as the Agreement would not be for sole supply.

Pricing for the products in the Agreement, subject to any prior termination of the Agreement, would not be increased before 1 March 2021.

Who we think will be interested

  • Suppliers and Wholesalers
  • DHB Staff:
    • Wound Care Clinicians
    • Community Nursing Services
    • Clinical Engineers
    • Procurement Officers

About NPWT 

NPWT uses a vacuum dressing that can promote wound healing by drawing fluid away from the wound and increasing blood flow to the wound.

A NPWT system typically includes a disposable or reusable pump to create the vacuum, and associated consumable products to seal the wound and to manage excess fluid.  A NPWT system may also include a mechanism to instil wound cleaning fluids.

NPWT can be used in both hospital and community settings.

Why we’re proposing this

In June 2017, a request for proposals (RFP) was issued for NPWT Products. The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule under a range of procurement options including purchase, lease, rent, rent-to-buy and supplier provided equipment options.

PHARMAC has been working with a range of suppliers to seek provisional agreements and this proposal is the second to arise from that process.  Further consultations in this category are expected over the next few months.

Details about our proposal

PHARMAC has entered into a provisional Agreement with Protec for the supply of NPWT Products to DHBs that would result in listing 94 products on the Pharmaceutical Schedule from 1 March 2018.

Brands of reusable NPWT units and procurement options included in the Agreement are:

Brand

Procurement options

Exsudex NPWT hospital unit 
(with optional upgrade to include instillation mechanism)

Purchase, daily rental, monthly rental, fleet rental. 

Exsudex NPWT hospital/home care unit

Purchase, daily rental, monthly rental, fleet rental

Brands of NPWT consumables included in the Agreement are:

  • Exsudex
  • Coldex
  • Sufasoft
  • Cavasan
  • Kerlix

Pricing has not been included in this consultation but has been made available to Procurement Departments at DHBs.

DHBs would be able to continue to choose which NPWT Products they procure.

The Agreement includes terms for training and education services to be provided by Protec to DHB personnel on appropriate use of its NPWT Products, which is to be provided at times as agreed with individual DHBs.

The Agreement sets out respective responsibilities for maintenance and management of equipment under the various procurement options.

To provide feedback

Send an email to denise.mundy@pharmac.govt.nz by 4pm, Friday 2 February 2018.

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.